Neurofibromatosis type 2
Citation Manager Formats
Make Comment
See Comments

A 45-year-old woman developed a gradual onset of sensorineural hearing loss in the left ear in 1984. Head CT scan with contrast demonstrated bilateral cerebellopontine angle (CPA) enhancing masses. She underwent a resection of the left CPA tumor with pathology confirming schwannoma. Despite several resections, she had progressive hearing loss and she became deaf in 2003. Her brain MRI (figure) demonstrated bilateral vestibular schwannomas, which are sufficient for a definite diagnosis of neurofibromatosis type 2 (NF-2), according to the National Institutes of Health, Manchester, or National Neurofibromatosis Foundation diagnostic criteria.1 In addition, this patient also has multiple meningiomas, which are associated with NF-2.2 The patient has been treated with imatinib mesylate (Gleevec) plus hydroxyurea in a clinical trial for her progressive meningiomas. At her last follow-up visit, she was neurologically and radiographically stable after 12 months of treatment.
Figure. T1-weighted MRI revealed large gadolinium-enhancing masses in bilateral cerebellopontine angles (large white arrows) with extension into the internal auditory canals (small white arrows), characteristic of vestibular schwannomas. Several extra-axial enhancing masses were present in the posterior fossa and the right middle cranial fossa (black arrows), consistent with meningiomas.
Footnotes
-
Disclosure: The authors report no conflicts of interest.
Received August 11, 2006. Accepted in final form November 27, 2006.
References
- 1.↵
Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 2002;59:1759–1765.
- 2.↵
Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 2000;54:71–76.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.